Company Overview

Fineotex Chemical Limited (BSE: 533333, NSE: FCL) reported strong financial performance for FY 2025-26 with significant growth across key metrics, alongside major corporate actions and comprehensive ESG disclosures.

Financial Performance

Consolidated Results: Revenue from operations surged 45% YoY to ₹7,722.26 crore (₹77,222.56 lakhs), while profit after tax increased 14.5% to ₹125.02 crore (₹12,501.51 lakhs). Earnings per share stood at ₹1.09.

Standalone Performance: Total income reached ₹437.97 crore with PAT of ₹91.89 crore. The company demonstrated robust operational performance with profit before tax of ₹113.45 crore on standalone basis.

Capital Structure Changes

The company executed significant capital restructuring including:

  • Sub-division of equity shares from ₹2 to ₹1 face value effective October 31, 2025
  • 4:1 bonus issue allocating 91.66 crore shares on November 3, 2025
  • Conversion of 18.75 lakh warrants into 1.875 crore equity shares
  • Paid-up capital increased from ₹22.92 crore to ₹116.45 crore

Dividend Distribution

  • Interim dividend of ₹0.80 per share (40%) already paid for FY25-26
  • Final dividend of ₹0.05 per share recommended, subject to shareholder approval at 23rd AGM on September 11, 2026
  • Total dividend payout for FY26 amounts to ₹14.99 crore

Corporate Governance & AGM Matters

The 23rd Annual General Meeting is scheduled for September 11, 2026 to approve:

  • Adoption of audited financial statements
  • Final dividend declaration
  • Re-appointment of Mrs. Aarti Mitesh Jhunjhunwala as director
  • Special resolutions for ₹800 crore fundraising through equity/security issuance
  • Approval of ₹500 crore related party transactions with subsidiaries

Fundraising & Strategic Initiatives

The board seeks shareholder approval to raise up to ₹800 crore through various instruments including equity shares, convertible securities, and warrants via private placement, FPO, or preferential issue. The company also plans significant related party transactions worth ₹500 crore with subsidiaries Fineotex Biotex Healthguard FZE and CrudeChem Technology LLC.

ESG & Sustainability Performance

Comprehensive BRSR disclosure shows:

  • 100% workforce coverage under health and accident insurance
  • Zero lost time injuries, fatalities, or recordable safety incidents
  • 100 KW solar panel installation at Ambernath manufacturing facility
  • GHG emissions: Scope 1 - 162.36 MT CO2e, Scope 2 - 330.32 MT CO2e
  • CSR expenditure of ₹11.88 lakh against obligation of ₹18.30 lakh

Subsidiary Performance & Investments

Significant investments in subsidiaries including ₹44.28 crore in Fineotex Biotex Healthguard FZE. Subsidiaries contributed substantially to consolidated performance, with CrudeChem Technology LLC accounting for 30.68% of profit (₹33.36 crore).

Regulatory Compliance & Subsequent Events

The company submitted revised Annual Report to correct typographical errors with no material changes. Minor GST dispute of ₹3.44 lakh under appeal. Post-year settlement of legal dispute involving ₹6.18 crore payment recorded in FY26 accounts.

Credit Rating & Future Outlook

ICRA reaffirmed A+ (Positive) rating for long-term and A1+ for short-term borrowings. The company commissioned new manufacturing facility at Ambernath with 15,000 MT additional capacity, supporting future growth prospects.

Voting & Shareholder Information

Remote e-voting period from September 8-10, 2026 with record date of September 4, 2026. Shareholders encouraged to update PAN, KYC details, and register for electronic communication.